肾康注射液联合血液透析治疗慢性肾功能衰竭的临床效果及对肾功能、营养指标的影响

目的探讨肾康注射液联合血液透析治疗对慢性肾功能衰竭患者的肾功能、营养指标及临床疗效的影响。方法选取2018年3月~2019年2月我院肾内科收治的116例慢性肾功能衰竭患者作为研究对象,随机分为对照组和观察组各58例。对照组给予单纯血液透析治疗,观察组给予肾康注射液联合血液透析治疗,治疗16周后观察两组患者的肾功能及肾纤维化指标、营养及贫血指标改善情况,并比较两组患者的临床疗效、不良反应发生情况。结果治疗16周后,两组患者的血肌酐(Scr)、尿素氮(BUN)、Ⅳ型胶原(C-Ⅳ)、透明质酸(HA)、Ⅲ型前胶原(PC-Ⅲ)均较治疗前降低(均P<0.05),纤维连接蛋白(FN)较治疗前升高(均P<0.05),而两组患者各指标比较,观察组的改善效果优于对照组(均P<0.05)。两组患者的红细胞总数(RBC)、血红蛋白(HGB)、血清总蛋白(TP)、血清白蛋白(ALB)水平均较治疗前改善(均P<0.05),观察组的改善效果明显优于对照组(均P<0.05)。两组患者治疗前后的血铁(Fe)、转铁蛋白(TRF)、铁蛋白(FER)、促红细胞生成素(EPO)水平比较,对照组各指标水平均较治疗前降低(均P<0.05),观察组治疗前后各指标水平比较无差异性(均P>0.05)。两组患者的临床疗效比较,观察组总有效率(86.21%)明显高于对照组(60.34%),差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论肾康注射液联合血液透析治疗慢性肾功能衰竭能明显改善患者肾功能及营养状况,提高临床疗效,且安全性高,值得临床推广。

Clinical effect of Shenkang Injection Combined with hemodialysis in the treatment of chronic renal failure and its influence on renal function and nutritional indexes

Objective To investigate the effect,renal function and nutritional indexes of Shenkang injection combined with hemodialysis in patients with chronic renal failure.Methods A total of 116 hemodialysis patients admitted to the Department of Nephrology,Second People's Hospital of Guangdong Province from March 2018 to February 2019 were selected as subjects.They were divided into 2 groups according to the random principle.The control group(56 cases)received hemodialysis treatment,and the observation group(56 cases)received Shenkang injection combined with hemodialysis treatment.After 16 weeks of treatment,the renal function and renal fibrosis index,nutrition and anemia indicators were observed in the two groups,and the efficacy and adverse reactions of the two groups were compared.Results After 16 weeks of treatment,serum creatinine(Scr),urea nitrogen(BUN),typeⅣcollagen(C-Ⅳ),hyaluronic acid(HA),and typeⅢpro-gel(PC-Ⅲ)were lower in the observation group than before treatment(P<0.05 for each).Fibronectin(FN)was higher than before treatment(P<0.05);The total number of red blood cells(RBC),hemoglobin(HGB),serum total protein(TP)and serum albumin(ALB)in the observation group were significantly higher than those before treatment(P<0.05for each).There were no significant changes in blood iron(Fe),transferrin(TRF),ferritin(FER)and erythropoietin(EPO)levels in the observation group before and after treatment(P>0.05for each).The total effective rate of the observation group(86.21%)was significantly higher than that of the control group(60.34%),and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Shenkang injection combined with hemodialysis treatment can protect renal function of CRF patients,improve nutritional status,and improve clinical treatment effect.It is safe and worthy of clinical promotion.